Clinilabs invites you to their event
About this event
Unmet needs in epilepsy therapy include improving the ratio of patients who respond to treatment (approximately 2 out of 3). We also need therapies that are disease modifying, and that address the difficult and intractable pediatric epilepsy syndromes. It is also important to recognize that patients need medications that are better tolerated and safe.
Hosted by
Ms. Jeanine Falinski, VP of Strategy and Corporate Development, has more than 20 years of experience in the pharmaceutical industry. Jeanine graduated from Emerson College with a degree in New Media and Marketing, later on receiving her MBA in Pharmaceutical Management from Drexel University.
Dr. French is a professor of Neurology in the Comprehensive Epilepsy Center at NYU Langone School of Medicine and Founder/Director of the Epilepsy Study Consortium, an academic group that has performed a number of early phase clinical trials in epilepsy.
We are a global, full-service contract research organization (CRO), the only one focused exclusively on central nervous system (CNS) drug development. We are dedicated to bringing new therapies to patients living with mental health, neurological and substance abuse disorders.
